Neurocrine Biosciences CCO Eric Benevich Reports PRSU Vesting and Tax Withholding

Overview & Context

On September 15, 2026, Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc ($NBIX), reported equity compensation-related transactions that took place on September 11, 2026.

Transaction Breakdown

1. Performance RSU Vesting (Code A):

   • Shares Acquired: 6,275 shares of Common Stock at $0.00.
   • Details: Achievement of a specific performance metric associated with previously granted Performance Restricted Stock Units (PRSUs) was certified on September 11, 2026.
   • Post-Transaction Holdings: 70,683 shares.

2. Tax Withholding (Code F):

   • Shares Disposed: 3,386 shares withheld to satisfy statutory tax obligations triggered by the PRSU vesting.
   • Price Per Share: $156.22.
   • Total Value Withheld: $528,960.92.
   • Post-Transaction Holdings: 67,297 shares directly owned.

Market & Strategic Significance

• Trading Significance: Low.
• Rationale: The transaction represents standard equity award settlement and mandatory tax withholding rather than discretionary open-market buying or selling. The executive continues to maintain a substantial direct equity stake of 67,297 shares in the company.